Search results
Showing 16 to 30 of 36 results for irritable bowel syndrome
and tolerability of bile acid sequestrants among people with irritable bowel syndrome (IBS-D) or Crohn's disease without...
safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most...
is a primary or secondary condition in people diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...
management of [Irritable bowel syndrome] (IBS) symptoms, either as first-line therapies in primary care, or in the...
malabsorption in people with chronic diarrhoea diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...
(DG11): “Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel”. Recommendation 1.1 in the guidance states: Faecal...
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
Evaluation of guidelines for the use of faecal calprotectin testing in primary care
it is used to support a diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). The...
Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
This quality standard covers diagnosing, assessing and managing food allergy in children and young people (under 19) and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS118Show all sections
Sections for QS118
- Quality statements
- Quality statement 1: Allergy-focused clinical history
- Quality statement 2: Diagnosing IgE-mediated food allergy
- Quality statement 3: Diagnosing non-IgE-mediated food allergy
- Quality statement 4: Referral to secondary or specialist care
- Quality statement 5 (placeholder): Diagnosing food allergy in adults
- Quality statement 6 (placeholder): Nutritional support for food allergy
- Update information
Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)
This evidence summary has been updated and replaced by NICE guideline CG61.
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)
We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.